Inspire Medical Systems, Inc. (INSP)

Inspire Medical Systems' stock has experienced significant volatility and a notable decline over the past six months (November 2025 - May 2026). Key events impacting the stock include the Q4 2025 earnings release, the Q1 2026 earnings release and guidance cut due to Medicare coding and reimbursement challenges, analyst downgrades and price target cuts following the revised guidance, the Annual General Meeting where stockholders approved an amended incentive award plan and governance changes, and a proposed class action lawsuit alleging that Inspire misled investors about the readiness and demand for its Inspire V launch.

Inspire Medical Systems, Inc. experiences demand seasonality for its products and services. Management expects sequential sales growth in the third quarter from the second quarter, with a larger increase anticipated in the fourth quarter, attributing this pattern to seasonality. The company also expects challenges related to coding and reimbursement uncertainty to persist through the balance of 2026, but anticipates a return to revenue growth in 2027.

Inspire Medical Systems, Inc. (INSP) is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea (OSA). Operating in the Healthcare sector, specifically Medical Devices and Therapeutic Devices, its primary product is the Inspire system, a neurostimulation technology that treats moderate to severe OSA by stimulating the hypoglossal nerve to maintain airway patency during sleep. The Inspire system includes an implantable pulse generator, a sensing lead, and a stimulation lead.

Inspire Medical Systems, Inc. operates in the United States, Europe, and the Asia Pacific region. The majority of its revenue comes from the United States, with sales of the Inspire system also in selected countries in Europe and the Asia Pacific region through a direct sales organization and distributors in places like Japan, Singapore, and Hong Kong. The company is headquartered in Golden Valley, Minnesota.

Inspire Medical Systems generally maintains a position as a leader in the medical device industry for obstructive sleep apnea treatment. However, in the past year, the company's reputation has been significantly impacted by the challenges surrounding the rollout and reimbursement of its Inspire V system. The revised financial guidance and the acknowledgment of "persistent reimbursement and coding challenges" have created uncertainty among investors and analysts. The proposed class action lawsuit alleging the company misled investors about the Inspire V launch also represents a direct challenge to its brand reputation.

Inspire Medical Systems, Inc. has a significant institutional ownership base. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Wellington Management Group Llp, Deerfield Management Company, L.p. (series C), Morgan Stanley, D. E. Shaw & Co., Inc., William Blair Investment Management, Llc, State Street Corp, Artisan Partners Limited Partnership, and Fuller & Thaler Asset Management, Inc. These institutions collectively hold a substantial number of shares.